-- Completed enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial and increased trial size to 121 patients based on Part B patient demand -- -- Bempikibart Phase 2 topline results in AD and alopecia areata (AA) remain on-track for Q4'24 -- -- Enrolling patients in the Phase 2 basket trial of ADX-097 for complement mediated renal diseases; initial open-label data expected by year-end 2024 and topline results in 2H'25 -- -- Cash, cash equivalents, and short-term investments of $107.6 million as of June 30, 2024 , expected to provide financial runway through four Phase 2 clinical milestones and into mid-2026 -- WALTHAM, Mass. , Aug.
8, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB ) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended June 30, 2024 , and provided recent corporate updates. "Q32 Bio made strong progress advancing both bempikibart and ADX-097 in Phase 2 clinical trials," said Jodie Morrison , Chief Executive Officer of Q32 Bio.
"We completed enrollment in the Phase 2 clinical trial of bempikibart in AD, exceeding our initial enrollment target due to strong patient demand, and we look forward to sharing topline results from the Phase 2 clinical trials in AD and AA in the fourth quarter of 2024." "Additionally, we are enrolling patients in our Phase 2 basket trial of ADX-097 for complement mediated renal diseases. We ex.